FOLD - NASDAQ
Amicus Therapeutics, Inc.
$14.49
+0.0000%Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
At a Glance
Live SnapshotAmicus Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Amicus Therapeutics, Inc. Cash Flow Statement
FOLD • NASDAQ
| Amicus Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-27.1M | -56.1M | -151.6M | -236.6M | -250.5M | -276.9M | -356.4M | -349M | -284M | -200M | -132.1M | -68.9M | -59.6M | -48.8M | -44.4M | -54.9M | -6.6M | -39.4M | -41.2M | -46.3M | |
2.6M | 8.5M | 7.9M | 5.3M | 6.2M | 8.8M | 4.8M | 4.2M | 3.6M | 3.2M | 1.8M | 1.5M | 1.7M | 1.7M | 1.6M | 2.1M | 2.1M | 1.5M | 1.2M | 952.5K | |
0.0 | 0.0 | -4.9M | 9K | 34K | -155K | -1.4M | 6M | -167.3M | -3.7M | 952K | 0.0 | -908K | 0.0 | 0.0 | 121K | 0.0 | -6.4M | -2.8M | 0.0 | |
87.4M | 84.9M | 86.1M | 76.5M | 57.8M | 49.2M | 44.4M | 29.3M | 23.1M | 17.5M | 10M | 6M | 6.2M | 6.2M | 8.7M | 6.2M | 7.8M | 6.4M | 2.8M | 0.0 | |
9.9M | 27.7M | 41.5M | 28M | 2.5M | 17.8M | 46.6M | 14.3M | 234.9M | 31.4M | 4.9M | 314K | 2M | -625K | -2.8M | 1.4M | 195K | 6.4M | 4.1M | 4.5M | |
(0.0) | (8.2M) | (8.5M) | (1.1M) | (20M) | (10.4M) | (691K) | (1.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-39.6M | -98.9M | -48M | -39.9M | -18.6M | -32.1M | 11.6M | -4.7M | -25.8M | 1.1M | 14.3M | 9.4M | 4.9M | 7.8M | -12.5M | 31.2M | -46.9M | -5.5M | 51M | 7M | |
33.1M | -33.9M | -69.1M | -166.6M | -202.5M | -233.3M | -250.4M | -300M | -215.5M | -150.5M | -100.1M | -51.7M | -45.8M | -33.7M | -49.4M | -14M | -43.4M | -36.9M | 15.2M | -33.9M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-3.3M | -3.6M | -7.4M | -3.8M | -3.9M | -3.2M | -20M | -6.3M | -4.5M | -6M | -4.8M | -238K | -695K | -4.3M | -1.4M | -384K | -1.8M | -2.7M | -669K | -2M | |
(0.0) | (0.0) | (0.0) | (3.4M) | (0.0) | (0.0) | (0.0) | (6.3M) | (0.0) | (0.0) | -141.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-94.4M | -114.8M | -91.7M | -243.3M | -341.4M | -365.2M | -383.9M | -578.4M | -490.5M | -219.9M | -289.6M | -162.8M | -56.6M | -118.5M | -50.6M | -113.7M | -98.2M | -153.7M | -200.7M | -62M | |
51.3M | 117.8M | 197.2M | 335.9M | 424M | 354.8M | 499M | 463.5M | 323.8M | 221.4M | 290.1M | 55.9M | 83.3M | 83.4M | 98.5M | 94.6M | 131.8M | 178.1M | 126.4M | 37.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -6.3M | -166.7M | 1.4M | 534K | -106.8M | 26.8M | -35.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-46.4M | -560K | (98.1M) | (92.3M) | (78.8M) | -13.6M | (95.2M) | -121.2M | -171.2M | -4.5M | -145.3M | -107.1M | (26.1M) | -39.4M | (46.5M) | -19.4M | (31.9M) | (21.7M) | -75M | -26.6M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
19.2M | 27.2M | 92.9M | -7.2M | 199.8M | 0.0 | 189M | 294.6M | 243M | 97.1M | 243M | 135.8M | 15M | 80.2M | 0.0 | 45.2M | 0.0 | 530K | 92.8M | 63.6M | |
-272K | -97K | -21M | -283K | -479K | 230.6M | -420K | 146.3M | -308K | 192.3M | 34.7M | -299K | 14.5M | -347K | -1.3M | -1.6M | 2.7M | -1.5M | -1.4M | -880.7K | |
(0.0) | (0.0) | (0.0) | -11.5M | (0.0) | (0.0) | (0.0) | -2.8M | -1.6M | -1.3M | -2M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-18.3M | -22M | -20.6M | 0.0 | 12.8M | 32.3M | 28.9M | 9.9M | 4.7M | -16.7M | 13.1M | 3.7M | -110K | 1.6M | 359K | 9K | 60K | 0.0 | 546K | 3.4M | |
610K | 5.1M | 61.7M | -7.5M | 212.1M | 262.9M | 217.5M | 450.8M | 247.4M | 272.7M | 290.9M | 139.2M | 29.4M | 81.5M | -934K | 43.7M | 2.8M | -998K | 91.9M | 66.2M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
13.3M | -4M | 6.3M | -14.6M | -5M | 3.8M | 1.7M | 1.5M | 1.3M | -131K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
600K | -33.4M | 97M | -96.3M | 83.3M | 19.8M | 64M | 31.1M | -138M | 117.5M | 45.4M | -19.6M | 9.7M | 8.3M | -3.9M | 10.2M | -8.7M | -16.1M | 32.1M | 5.7M | |
216.7M | 250.1M | 153.1M | 249.5M | 166.2M | 146.3M | 82.4M | 51.2M | 187M | 69.5M | 24.1M | 43.6M | 34M | 25.7M | 29.6M | 19.3M | 28.1M | 44.2M | 12.1M | 6.4M | |
217.3M | 216.7M | 250.1M | 153.1M | 249.5M | 166.2M | 146.3M | 82.4M | 49.1M | 187M | 69.5M | 24.1M | 43.6M | 34M | 25.7M | 29.6M | 19.3M | 28.1M | 44.2M | 12.1M | |
29.8M | -37.4M | -76.5M | -170.3M | -206.4M | -236.5M | -270.4M | -306.3M | -220M | -156.5M | -105M | -51.9M | -46.5M | -38.1M | -50.8M | -14.4M | -45.2M | -39.5M | 14.5M | -35.9M |
SEC Filings
FOLD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 20, 2026 | February 20, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 20, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 26, 2026 | January 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 19, 2025 | December 19, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 31, 2025 | July 31, 2025 | 2025 |
Related Guides
Continue your FOLD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.